Answers are grounded in this paper and cite their sources.
Background/Objectives: Ursodeoxycholic acid (UDCA) and omega-3 fatty acids act on partly distinct hepatic pathways, but their effects on steatotic liver disease remain understudied. We evaluated a UDCA/biphenyl dimethyl dicarboxylate (BDD) complex and omega-3 fatty acids, alone and combined, in mice with high-fat diet-induced hepatic steatosis. Methods: Male C57BL/6J mice were fed a high-fat diet for 8 weeks and then gavaged 6 days per week with vehicle, UDCA/BDD complex, omega-3, or both for 12 weeks on the same diet. Steatosis was graded by ultrasonography every 4 weeks. Histology, immunohistochemistry, serum biochemistry, and targeted quantitative real-time polymerase chain reaction (qPCR) were assessed at the end of treatment. Hepatic transcriptome data from one animal per group are provided as supplementary exploratory data. Results: Ultrasonographic steatosis grades were lower in all treatment groups, and histological steatosis was lowest with UDCA/BDD (p = 0.031 versus Control), without ballooning or relevant fibrosis. Serum aspartate aminotransferase was lowest with the combination, with a significant omega-3 effect and no detectable interaction. The stearoyl-CoA desaturase 1 (SCD1) immunohistochemical score was lower in all treatment groups than in Control. The reduction in Scd1 mRNA in the combination group was nominal and did not persist after multiple-testing correction. Conclusions: The UDCA/BDD complex and omega-3 fatty acids, alone or combined, were associated with lower ultrasonographic and histological steatosis. The combination was numerically favorable for some outcomes but was not superior to monotherapy, and no statistically significant interaction was detected. These findings support further evaluation in models of steatohepatitis and fibrosis.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: